243 related articles for article (PubMed ID: 644461)
1. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Wood WC; Cosimi AB; Carey RW; Kaufman SD
Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
[TBL] [Abstract][Full Text] [Related]
3. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
[TBL] [Abstract][Full Text] [Related]
5. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
6. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
Mitchell MS; Mokyr MB; Davis JM
J Clin Invest; 1977 Jun; 59(6):1017-26. PubMed ID: 863999
[TBL] [Abstract][Full Text] [Related]
7. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
[TBL] [Abstract][Full Text] [Related]
8. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
Balch CM; Murray D; Presant C; Bartolucci AA
Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
[TBL] [Abstract][Full Text] [Related]
10. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.
Gutterman JU; Mavligit G; Gottlieb JA; Burgess MA; McBride CE; Einhorn L; Freireich EJ; Hersh EM
N Engl J Med; 1974 Sep; 291(12):592-7. PubMed ID: 4851001
[No Abstract] [Full Text] [Related]
11. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
[TBL] [Abstract][Full Text] [Related]
13. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
14. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
Pullmann H; Muth M
Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
[No Abstract] [Full Text] [Related]
15. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
[TBL] [Abstract][Full Text] [Related]
17. Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
Peter HH; Deutschmann KE; Deinhardt J; Deicher H
Recent Results Cancer Res; 1978; 68():367-74. PubMed ID: 752872
[No Abstract] [Full Text] [Related]
18. Surgical treatment of malignant melanoma.
Rosenberg SA
Cancer Treat Rep; 1976 Feb; 60(2):159-63. PubMed ID: 769968
[TBL] [Abstract][Full Text] [Related]
19. Modified stage I (T1N0M0, T2N0M0), nonsmall cell lung cancer: treatment results, recurrence patterns, and adjuvant immunotherapy.
Little AG; DeMeester TR; Ferguson MK; Skinner DB; Hoffman PC; Skosey C; Blough RR; Golomb HM
Surgery; 1986 Oct; 100(4):621-8. PubMed ID: 3020725
[TBL] [Abstract][Full Text] [Related]
20. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
